Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicine development, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, February 11th at 2:40 p.m. ET.
Investors and interested parties can access both the live event and replay through the investor relations section of Regulus' website at https://ir.regulusrx.com/events. The presentation recording will remain accessible for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – RGLS
In the trading session that priced this news, RGLS gained 8.94%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366886.html
SOURCE Regulus Therapeutics Inc.